Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
KOOL's Cash to Debt is ranked higher than
89% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. KOOL: No Debt )
KOOL' s 10-Year Cash to Debt Range
Min: 3   Max: No Debt
Current: No Debt

Equity to Asset 0.77
KOOL's Equity to Asset is ranked higher than
84% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. KOOL: 0.77 )
KOOL' s 10-Year Equity to Asset Range
Min: 0.72   Max: 0.88
Current: 0.77

0.72
0.88
Interest Coverage No Debt
KOOL's Interest Coverage is ranked higher than
91% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. KOOL: No Debt )
KOOL' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: -0.55
M-Score: 84.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -56.55
KOOL's Operating margin (%) is ranked higher than
50% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.93 vs. KOOL: -56.55 )
KOOL' s 10-Year Operating margin (%) Range
Min: -211.11   Max: -9.09
Current: -56.55

-211.11
-9.09
Net-margin (%) -53.99
KOOL's Net-margin (%) is ranked higher than
50% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. KOOL: -53.99 )
KOOL' s 10-Year Net-margin (%) Range
Min: -213.33   Max: -3.03
Current: -53.99

-213.33
-3.03
ROE (%) -34.80
KOOL's ROE (%) is ranked higher than
53% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.73 vs. KOOL: -34.80 )
KOOL' s 10-Year ROE (%) Range
Min: -141.18   Max: -13.56
Current: -34.8

-141.18
-13.56
ROA (%) -27.07
KOOL's ROA (%) is ranked higher than
52% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. KOOL: -27.07 )
KOOL' s 10-Year ROA (%) Range
Min: -106.67   Max: -10.6
Current: -27.07

-106.67
-10.6
ROC (Joel Greenblatt) (%) -134.95
KOOL's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. KOOL: -134.95 )
KOOL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -231.71   Max: -36.5
Current: -134.95

-231.71
-36.5
Revenue Growth (%) -25.20
KOOL's Revenue Growth (%) is ranked lower than
51% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. KOOL: -25.20 )
KOOL' s 10-Year Revenue Growth (%) Range
Min: -25.2   Max: 20.4
Current: -25.2

-25.2
20.4
EBITDA Growth (%) 27.30
KOOL's EBITDA Growth (%) is ranked higher than
93% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. KOOL: 27.30 )
KOOL' s 10-Year EBITDA Growth (%) Range
Min: -38.9   Max: 270.2
Current: 27.3

-38.9
270.2
EPS Growth (%) 28.40
KOOL's EPS Growth (%) is ranked higher than
90% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. KOOL: 28.40 )
KOOL' s 10-Year EPS Growth (%) Range
Min: -36.4   Max: 278
Current: 28.4

-36.4
278
» KOOL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

KOOL Guru Trades in Q2 2013

Jim Simons 191,000 sh (+2.85%)
» More
Q3 2013

KOOL Guru Trades in Q3 2013

Jim Simons 222,000 sh (+16.23%)
» More
Q4 2013

KOOL Guru Trades in Q4 2013

Jim Simons 187,700 sh (-15.45%)
» More
Q1 2014

KOOL Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KOOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2011-09-30 Sold Out 0.0001%$1.2 - $2.13 $ 1.13-35%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.93
KOOL's P/B is ranked higher than
94% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. KOOL: 0.93 )
KOOL' s 10-Year P/B Range
Min: 0.16   Max: 5.18
Current: 0.93

0.16
5.18
P/S 1.53
KOOL's P/S is ranked higher than
80% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. KOOL: 1.53 )
KOOL' s 10-Year P/S Range
Min: 0.18   Max: 6.52
Current: 1.53

0.18
6.52
EV-to-EBIT -3.48
KOOL's EV-to-EBIT is ranked higher than
57% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 34.56 vs. KOOL: -3.48 )
KOOL' s 10-Year EV-to-EBIT Range
Min: -17.3   Max: 1.7
Current: -3.48

-17.3
1.7
Current Ratio 3.97
KOOL's Current Ratio is ranked higher than
81% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. KOOL: 3.97 )
KOOL' s 10-Year Current Ratio Range
Min: 2.68   Max: 12.49
Current: 3.97

2.68
12.49
Quick Ratio 3.09
KOOL's Quick Ratio is ranked higher than
80% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. KOOL: 3.09 )
KOOL' s 10-Year Quick Ratio Range
Min: 1.55   Max: 11.74
Current: 3.09

1.55
11.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 56.50
KOOL's Price/Net Cash is ranked higher than
84% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. KOOL: 56.50 )
KOOL' s 10-Year Price/Net Cash Range
Min: 0.85   Max: 69.5
Current: 56.5

0.85
69.5
Price/Net Current Asset Value 6.65
KOOL's Price/Net Current Asset Value is ranked higher than
90% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. KOOL: 6.65 )
KOOL' s 10-Year Price/Net Current Asset Value Range
Min: 0.54   Max: 62.52
Current: 6.65

0.54
62.52
Price/Tangible Book 3.32
KOOL's Price/Tangible Book is ranked higher than
77% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 6.00 vs. KOOL: 3.32 )
KOOL' s 10-Year Price/Tangible Book Range
Min: 0.38   Max: 19.85
Current: 3.32

0.38
19.85
Price/Median PS Value 1.15
KOOL's Price/Median PS Value is ranked higher than
67% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.13 vs. KOOL: 1.15 )
KOOL' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 11.69
Current: 1.15

0.22
11.69
Earnings Yield (Greenblatt) -28.70
KOOL's Earnings Yield (Greenblatt) is ranked lower than
53% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. KOOL: -28.70 )
KOOL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 58   Max: 9706.9
Current: -28.7

58
9706.9
Forward Rate of Return (Yacktman) -41.54
KOOL's Forward Rate of Return (Yacktman) is ranked higher than
52% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.44 vs. KOOL: -41.54 )
KOOL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -174.1   Max: -11.7
Current: -41.54

-174.1
-11.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:THRA.Germany
Thermogenesis Corporation was incorporated in Delaware in July 1986. The Company designs, manufactures and markets automated and semi-automated devices and single-use processing disposables that enable hospitals and blood banks to manufacture a therapeutic dose of stem cells. Initially, the Company developed medical devices for ultra rapid freezing and thawing of blood components, which the Company manufactures and distributes to blood banks and hospitals. The Company's products automate the volume reduction and cryopreservation process of adult stem cell concentrates from cord blood and bone marrow for use in laboratory and point of care settings. It currently sells its products in approximately 37 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. It provides the tools necessary for the collection, separation, storage and delivery of stem cells from adult tissue sources including cord blood and bone marrow, and potentially in the future, adipose and placenta. These tools are being used by healthcare providers in both the laboratory and point of care settings. The Company's competitive advantage is achieved through applying its advanced research and engineering capabilities to develop a complete 'tool box' for healthcare providers advancing regenerative medicine. The Company's solutions enable its customers to automate their processes, comply with quality regulations and achieve high stem cell yields. The Company's medical devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign agencies.
» More Articles for KOOL

Headlines

Articles On GuruFocus.com
comment on KOOL Dec 01 2011 
comment on KOOL Aug 26 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
9:01 am Cesca Therapeutics announces it intends to embark on a nationwide search for a new CEO.... Oct 29 2014
Cesca Therapeutics Announces Change in Executive Leadership Oct 29 2014
Cesca Therapeutics Announces Agreement With New York Upstate Cord Blood Bank Oct 13 2014
Cesca Therapeutics to Present at Stem Cell Meeting on the Mesa Oct 06 2014
CESCA THERAPEUTICS INC. Financials Oct 04 2014
10-K for Cesca Therapeutics, Inc. Oct 01 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Sep 29 2014
Cesca Therapeutics Announces Approval of Its AXP(R) AutoXpress(R) System in Taiwan Sep 29 2014
Cesca Therapeutics Reports Fourth Quarter and Full Fiscal 2014 Results Sep 29 2014
Cesca Therapeutics Reschedules Fourth Quarter and Full Year Earnings Release Sep 25 2014
Q4 2014 Cesca Therapeutics Inc Earnings Release - After Market Close Sep 25 2014
Cesca Therapeutics to Announce Fourth Quarter and Fiscal 2014 Year End Results on September 25, 2014 Sep 23 2014
Cesca Therapeutics to Present at Aegis Healthcare & Technology Conference Sep 10 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Other Events Sep 10 2014
Cesca Therapeutics to Present at the Rodman & Renshaw(R) 16th Annual Global Investment Conference Sep 04 2014
Cesca Therapeutics Advocates Benefits of Cell Therapy to the Centers for Medicare and Medicaid... Aug 27 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers Aug 22 2014
Cesca Therapeutics and Fortis Healthcare Announce Master Collaboration Agreement Aug 05 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jun 16 2014
CESCA THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 13 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK